These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 22559757)
1. Update of the Dutch Manual for Costing in Economic Evaluations. Tan SS; Bouwmans CA; Rutten FF; Hakkaart-van Roijen L Int J Technol Assess Health Care; 2012 Apr; 28(2):152-8. PubMed ID: 22559757 [TBL] [Abstract][Full Text] [Related]
2. Update of the Dutch manual for costing studies in health care. Kanters TA; Bouwmans CAM; van der Linden N; Tan SS; Hakkaart-van Roijen L PLoS One; 2017; 12(11):e0187477. PubMed ID: 29121647 [TBL] [Abstract][Full Text] [Related]
3. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Oostenbrink JB; Koopmanschap MA; Rutten FF Pharmacoeconomics; 2002; 20(7):443-54. PubMed ID: 12093300 [TBL] [Abstract][Full Text] [Related]
4. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial. Mugford M; Hutton G; Fox-Rushby J Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluations and randomized trials in spinal disorders: principles and methods. Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis: can we reduce variability in costing methods? Adam T; Koopmanschap MA; Evans DB Int J Technol Assess Health Care; 2003; 19(2):407-20. PubMed ID: 12862197 [TBL] [Abstract][Full Text] [Related]
7. Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0. Kellerborg K; Perry-Duxbury M; de Vries L; van Baal P Value Health; 2020 Nov; 23(11):1453-1461. PubMed ID: 33127016 [TBL] [Abstract][Full Text] [Related]
8. Intersectoral Costs and Benefits of Mental and Behavioural Disorders in the Education Sector: an Exploration of Costing Methods. Bremmers LGM; Evers SMAA; Drost RMWA; Janssen LMM; Pokhilenko I; Paulus ATG; Norton EC; Yoon J; Cuddeback GS; Morrissey JP J Ment Health Policy Econ; 2020 Sep; 23(3):115-137. PubMed ID: 33411675 [TBL] [Abstract][Full Text] [Related]
9. Burden of illness of hip fractures in elderly Dutch patients. Kanters TA; van de Ree CLP; de Jongh MAC; Gosens T; Hakkaart-van Roijen L Arch Osteoporos; 2020 Jan; 15(1):11. PubMed ID: 31897865 [TBL] [Abstract][Full Text] [Related]
10. Generalisability in economic evaluation studies in healthcare: a review and case studies. Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708 [TBL] [Abstract][Full Text] [Related]
11. Costing bias in economic evaluations. Frappier J; Tremblay G; Charny M; Cloutier LM J Med Econ; 2015; 18(8):596-9. PubMed ID: 25800456 [TBL] [Abstract][Full Text] [Related]
12. Economic evaluations of health technologies in Dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators. Roseboom KJ; van Dongen JM; Tompa E; van Tulder MW; Bosmans JE BMC Health Serv Res; 2017 Jan; 17(1):89. PubMed ID: 28126005 [TBL] [Abstract][Full Text] [Related]
13. Assessing Costs Using the Treatment Inventory Cost in Psychiatric Patients (TIC-P), TIC-P Mini and TIC-P Midi. Kanters TA; Timman R; Zijlstra-Vlasveld MC; Muntingh A; Huijbregts KM; van Steenbergen-Weijenburg KM; Bouwmans CAM; van der Feltz-Cornelis CM; Hakkaart-van Roijen L J Ment Health Policy Econ; 2019 Mar; 22(1):15-24. PubMed ID: 30991352 [TBL] [Abstract][Full Text] [Related]
14. Unit Costs of Delinquent Acts for Use in Economic Evaluations. Reckers-Droog VT; Goorden M; Dijkgraaf MGW; Van Eeren HV; McCollister KE; Hakkaart-van Roijen L J Ment Health Policy Econ; 2019 Jun; 22(2):71-79. PubMed ID: 31319377 [TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY Value Health; 2014; 17(1):5-14. PubMed ID: 24438712 [TBL] [Abstract][Full Text] [Related]
16. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E; Value Health; 2013; 16(2):231-50. PubMed ID: 23538175 [TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of mandatory bicycle helmet use to prevent traumatic brain injuries and death. Reuvers R; Over EAB; Suijkerbuijk AWM; Polder JJ; de Wit GA; van Gils PF BMC Public Health; 2020 Mar; 20(1):413. PubMed ID: 32228524 [TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]